Cholinergic neurotransmission has different effects on cerebral glucose consumption and blood flow in young normals, aged normals, and Alzheimer's disease patients

NeuroImage

Volumn 6, Issue 4, 1997, Pages 335-343

  Blin, J ^a,b   Ivanoiu, A ^b   Coppens, A ^a   De Volder, A ^a   Labar, D ^a   Michel, C ^a   Laterre, E C ^b  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORINE 18; GLUCOSE; OXYGEN 15; PHYSOSTIGMINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN BLOOD FLOW; BRAIN METABOLISM; CHOLINERGIC TRANSMISSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GLUCOSE BRAIN LEVEL; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0031278962     PISSN: 10538119     EISSN: None     Source Type: Journal    
DOI: 10.1006/nimg.1997.0296     Document Type: Article

References (34)

1. Aubineau P., Sercombe R., Seylaz J. Parasympathomimetic influence of carbachol on local cerebral blood flow in the rabbit by a direct vasodilator action and an inhibition of the sympathetic-mediated vasoconstriction. Br. J. Pharmacol. 68:1980;449-459.
2. Baron J. C., Lebrun-Grandié P., Collard P., Crouzel C., Mestelan G. T., Bousser M. G. Non-invasive measurement of blood flow, oxygen consumption and glucose utilization in the same brain regions in man by positron emission tomography. J. Nucl. Med. 23:1982;391-399.
3. Blin J., Ray C. A., Chase T. N., Piercey M. Regional cerebral glucose metabolism compared in rodents and humans. Brain Res. 568:1991;215-222.
4. Blin J., Ray C., Piercey M., Bartko J. J., Mouradian M. M., Chase T. N. Comparison of cholinergic drug effects on regional brain glucose consumption in rats and humans by means of autoradiography and Positron Emission Tomography. Brain Res. 635:1994;196-202.
5. Blin J., Mazetti P., Mazoyer B., Rivaud S., Ben Ayed S., Malapani C., Pillon B., Agid Y. Does the enhancement of cholinergic neurotransmission influence brain glucose kinetics and clinical symptomatology in Progressive Supranuclear Palsy? Brain. 118:1995;1485-1495.
6. Blin J., Ivanoiu A., Coppens A., De Volder A., Bol A., Michel C., Labar D., Cogneau M., Melin J., Laterre E. C. Effect of physostigmine on brain glucose transporter activity in Alzheimer disease (AD) - An in vivo PET study. Neurology. 46:1996;P01.068.
7. Blin J., Ivanoiu A., De Volder A., Michel C., Bol A., Verellen C., Seron X., Duprez T., Laterre E. C. Physostigmine results in an increased decrement in brain glucose consumption in Alzheimer's disease. Psychopharmacology. 1997.
8. Bol A., Van Melkenbeke P., Michel C., Cogneau M., Goffinet A. M. Measurement of cerebral blood flow with a bolus of [150]-water: comparison of dynamic and integral methods. Eur. J. Nucl. Med. 17:1990;234-241.
9. Coppens A., Sibomana M., Bol A., Michel C. MEDIMAN, An object oriented approach for medical image analysis. IEEE Trans. Nucl. Sci. 40:1993;950-955.
10. Dacey R. G., Bassett J. E. Cholinergic vasodilatation of intracerebral arterioles in rats. Am. J. Physiol. 253:1987;H1253-H1260.
11. Edvinsson L., MacKenzie E. T., McCulloch J. Cerebral Blood Flow and Metabolism. 1993;Raven Press, New York.
12. Fellows L. K., Boutelle M. G., Fillenz M. Extracellular brain glucose levels reflect local neuronal activity: A microdialysis study in awake, freely moving rats. J. Neurochem. 59:1992;2141-2147.
13. Flynn D. D., Ferraridileo G., Levey A. I., Mash D. C. Differential alterations in muscarinic receptor subtypes in alzheimer's disease: Implications for cholinergic-based therapies. Life Sci. 56:1995;869-876.
14. Fox P. T., Raichle M. E., Mintun M. A., Dence C. Nonoxidative glucose consumption during focal physiologic neural activity. Science. 241:1988;462-464.
15. Frackowiak R. S. J., Lenzi G. L., Jones T., Heather J. D. Quantitative measurement of regional cerebral blood flow and oxygen metabolism in man, using 150 and positron emission tomography: theory, procedure and normal values. J. Comput. Assist. Tomogr. 4:1980;717-736.
16. Frackowiak R. S. J. Functional mapping of verbal memory and language. Trends Neurosci. 17:1994;109-115.
17. Francis P. T., Palmer A. M., Sims N. R. Neurochemical studies of early-onset Alzheimer' disease: Possible influence on treatment. N. Eng. J. Med. 313:1985;7-11.
18. Geaney D. P., Soper N., Shepstone B. J., Cowen P. J. Effect of central cholinergic stimulation on regional cerebral blood flow in Alzheimer disease. Lancet. 335:1990;1484-1487.
19. Gustafson L., Edvinsson L., Dahlgren N., Hagberg B., Risberg J., Rosén I., Fernö H. Intravenous physostigmine treatment of Alzheimer's disease evaluated by psychometric testing, regional cerebral blood flow (rCBF) measurement, and EEG. Psychopharmacology. 93:1987;31-35.
20. Heistad D. D., Marcus M. L., Said S. I., Gross P. M. Effect of acetylcholine and vasoactive intestinal peptide on cerebral blood flow. Am. J. Physiol. 239:1980;H73-H80.
21. Herholz K., Pietrzyk U., Karbe H., Würker M., Wienhard K., Heiss W.-D. Individual metabolic anatomy of repeating words demonstrated by MRI-guided positron emission tomography. Neurosci. Lett. 182:1994;47-50.
22. Hunter R., Wyper D. J., Patterson J., Hansen M. T., Goodwin G. M. Cerebral pharmacodynamics of physostigmine in Alzheimer's disease investigated using single-photon computerised tomography. Br. J. Psychiatr. 158:1991;351-357.
23. Matsuda M., Meyer J. S., Deshmukh V. D., Tagashira Y. Effect of acetylcholine on cerebral circulation. J. Neurosurg. 45:1976;423-431.
24. Mazziotta J. C., Phelps M. E. Positron emission tomography studies of the brain. Positron Emission Tomography and Autoradiography - Principles and Applications for the Brain and Heart. 1986;Raven Press, New York. p. 493-580.
25. Morris J. C., Mohs R. C., Rogers H., Fillenbaum G., Heyman A. Consortium to Establish a Registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. Psychopharmacol. Bull. 24:1988;641-644.
26. Phelps M. E., Huang S. C., Hoffmann E. J., Selin C., Sokoloff L., Kuhl D. E. Tomographic measurement of local cerebral glucose metabolic rate in humans with [F-18]2-fluoro-2-deoxy-D-glucose: Validation of method. Ann. Neurol. 6:1979;371-388.
27. Pietrzyk U., Herholz K., Fink G., Jacobs A., Mielke R., Slansky I., Würker M., Heiss W. D. An interactive technique for three-dimensional image registration: Validation for PET, SPECT, MRI, and CT brain studies. J. Nucl. Med. 35:1994;2011-2018.
28. Prohovnik I., Arnold S. E., Smith G., Lucas L. R. Physostigmine reversal of scopolamine-induced hypofrontality. J. Cereb. Blood Flow Metab. 17:1997;220-228.
29. A. Robillard, P. Demers, 1987, French version of the CERAD, Hôpital Maissonneuve-Rosemont, Montréal.
30. Scremin O. U. Pharmacological control of the cerebral circulation. Annu. Rev. Pharmacol. Toxicol. 31:1991;229-251.
31. Scremin O. U., Rovere A. A., Raynald A. C., Giardini A. Cholinergic control of blood flow in the cerebral cortex of the rat. Stroke. 4:1973;232-239.
32. Scremin O. U., Sonnenschein R. R., Rubinstein E. H. Cholinergic cerebral vasodilatation in the rabbit: Absence of concomitant metabolic activation. J. Cereb. Blood Flow Metab. 2:1982;241-247.
33. Sokoloff L. Relation between physiological function and energy metabolism in the central nervous system. J. Neurochem. 29:1977;13-26.
34. Wienhard K., Dahlbom M., Eriksson L., Michel C., Bruckbaurer T., Pietrzyk U., Heiss W. D. The ECAT EXACT HR: Performance of a new high resolution positron scanner. J. Comput. Assist. Tomogr. 18:1994;110-118.